Comparison Between Intralesional MMR vaccine and Intralesional Vit D in treatment of Plane Warts
Phase 4
- Conditions
- Health Condition 1: B078- Other viral warts
- Registration Number
- CTRI/2023/08/055966
- Lead Sponsor
- MAMC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Sex/Age: - Either sex from 18 â?? 60 years of age
2. Patients diagnosed with multiple plane warts ( >2) based on clinical examination.
Exclusion Criteria
1. Patients under any systemic or topical treatment of warts for the last four weeks
2. Patients with a past history of an allergic response to vaccine or drug
3. Patients with current acute febrile illness or any bacterial infection
4. Immunosuppressed patients (HIV/Immunodeficiency syndrome/Immunosuppressants
agents/etc.)
5. Pregnant or lactating women
6. Patients having past history of asthma, allergic skin disorders or convulsions
7. Patient refusal for consent
8. Treating physicianâ??s decision to give other treatment modality
9. Atypical, subclinical or dysplastic types of warts
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cure rate: Complete disappearance of disease/lesion before or after completing the course <br/ ><br>of treatment.Timepoint: four doses of two weekly injections. Final outcome to be seen 4 weeks after last dose.
- Secondary Outcome Measures
Name Time Method 1. Partial response to both the drugs will be assessed by decrease in size & total number <br/ ><br>using Visual Analog Scale. <br/ ><br>2. Frequency of Adverse Drug Reaction to both the drugs by using Naranjo ScaleTimepoint: 2 weekly dosage for 3 times followed by follow up after 1 month of last dose